Physician profile
Samuel M Alexander
NPI 1891709424
$19,379.81
in general payments reported to CMS, 2019-2025
30 companies · $992 in 2025
The $992 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.24 · 2020: $85.72 · 2021: $444 · 2022: $641 · 2023: $9,113 · 2024: $8,025 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Travel and Lodging: $561 · Food and Beverage: $556 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,000.00 |
| Travel and Lodging | $560.84 |
| Food and Beverage | $555.99 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $17,072.22 | 2021-2024 | Gelpoint V-Path |
| Bayer Healthcare Pharmaceuticals INC. | $963.79 | 2025 | |
| Momentis Surgical INC. | $393.00 | 2022 | |
| Abbvie INC. | $350.46 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Aspira Women'S Health INC | $86.08 | 2021-2024 | Ova1 |
| Evofem Biosciences, INC. | $75.27 | 2021-2023 | Phexxi |
| Pfizer INC. | $64.00 | 2019-2021 | |
| Avion Pharmaceuticals | $57.42 | 2020-2022 | |
| Organon LLC | $38.22 | 2021-2022 | |
| Intuitive Surgical, INC. | $34.93 | 2021 | |
| Ferring International Pharmascience Center US | $33.98 | 2021 | |
| Astellas Pharma US INC | $33.33 | 2023 | Myrbetriq, Veozah |
| Millicent US INC | $28.55 | 2023 | Femring, Intrarosa |
| Therapeuticsmd, INC. | $27.34 | 2022 | |
| Mylan Pharmaceuticals INC. | $22.55 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $21.95 | 2023-2025 | |
| Meditrina | $16.88 | 2025 | |
| Exeltis, USA INC. | $16.83 | 2020 | |
| Merck Sharp & Dohme LLC | $15.66 | 2021 | |
| Lsi Solutions INC | $14.17 | 2021 | |
| Renovia INC | $13.18 | 2021 |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.